文献速递膀胱癌与上尿路尿路上皮癌

上尿路尿路上皮癌的新辅助与辅助化疗:2020系统综述与荟萃分析及全身治疗未来展望

Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy.
PubMed 文献 · Eur Urol · 2020-08-12

该研究系统检索截至2020年2月的文献,荟萃分析新辅助化疗(NAC)和辅助化疗(AC)在上尿路尿路上皮癌(UTUC)根治性肾输尿管切除术(RNU)前后的疗效。NAC的病理完全缓解率为11%,总生存(OS)和癌症特异性生存(CSS)的合并风险比(HR)分别为0.44和0.38;AC的OS、CSS和DFS合并HR分别为0.77、0.79和0.52。AC证据等级更强(有1级证据),NAC最高为2级证据。

要点

  • NAC与RNU相比可改善OS和CSS,但证据最高为2级。
  • AC可改善OS、CSS和DFS,且有1级证据支持。
  • 化疗免疫联合治疗数据有限,但初步结果支持进一步研究。

核心结论

  • NAC可带来有利的病理缓解和肿瘤降期,并改善OS和CSS;AC可改善OS、CSS和DFS;AC证据强于NAC。

研究设计与样本

  • 系统综述与荟萃分析,检索Medline、Embase、Cochrane对照试验中心注册库及ASCO会议摘要至2020年2月。
  • 纳入研究NAC或AC用于UTUC的研究,多数为回顾性(2级证据),另有2项前瞻性随机试验提供1级证据。

主要发现

  • NAC的合并病理完全缓解率(≤ypT0N0M0)为11%(n=811),病理部分缓解率(≤ypT1N0M0)为43%(n=869),均基于14项研究。
  • NAC的OS合并HR为0.44(95%CI 0.32-0.59,p<0.001),CSS合并HR为0.38(95%CI 0.24-0.61,p<0.001),均基于6项研究。
  • AC的OS合并HR为0.77(95%CI 0.64-0.92,p=0.004),基于14项研究和7983例患者。
  • AC的CSS合并HR为0.79(95%CI 0.69-0.91,p=0.001),基于18项研究和5659例患者;DFS合并HR为0.52(95%CI 0.38-0.70),基于4项研究和602例患者。
  • 目前有4项新辅助免疫治疗2期试验和3项辅助免疫治疗2期试验正在进行。

临床怎么用

  • 对于UTUC患者,围手术期化疗可延长生存,AC证据更强(1级),NAC证据为2级,临床决策需结合证据等级和患者情况。

局限性

  • 多数研究为回顾性(2级证据),NAC证据最高仅为2级;化疗免疫联合治疗数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: To improve the prognosis of upper tract urothelial carcinoma (UTUC), clinicians have used neoadjuvant chemotherapy (NAC) or adjuvant chemotherapy (AC) before or after radical nephroureterectomy (RNU). Despite some new data, the evidence remains mixed on their efficacy. OBJECTIVE: To update the current evidence on the role of NAC and AC for UTUC. EVIDENCE ACQUISITION: We searched for all studies investigating NAC or AC for UTUC in Medline, Embase, the Cochrane Central Register of Controlled Trials, and abstracts from the American Society of Clinical Oncology meetings up to February 2020. A systematic review and meta-analysis was performed. EVIDENCE SYNTHESIS: For NAC, the pooled pathologic complete response rate (≤ypT0N0M0) was 11% (n = 811) and pathologic partial response rate (≤ypT1N0M0) was 43% (n = 869), both across 14 studies. Across six studies, the pooled hazard ratios (HRs) were 0.44 (95% confidence interval [CI]: 0.32-0.59, p < 0.001) for overall survival (OS) and 0.38 (95% CI: 0.24-0.61, p < 0.001) for cancer-specific survival (CSS) in favor of NAC. The evidence for NAC is at best level 2. As for AC, there was a benefit in OS (pooled HR 0.77; 95% CI: 0.64-0.92, p = 0.004 across 14 studies and 7983 patients), CSS (pooled HR 0.79; 95% CI: 0.69-0.91, p = 0.001 across 18 studies and 5659 patients), and disease-free survival (DFS; pooled HR 0.52; 95% CI: 0.38-0.70 across four studies and 602 patients). While most studies were retrospective (level 2 evidence), there were two prospective randomized trials providing level 1 evidence. There are currently four phase 2 trials on neoadjuvant immunotherapy and three phase 2 trials on adjuvant immunotherapy for UTUC. CONCLUSIONS: NAC for UTUC confers a favorable pathologic response and tumor downstaging rate, and an OS and CSS benefit compared with RNU alone. AC confers an OS, CSS, and DFS benefit compared with RNU alone. Currently, the evidence for AC appears stronger (with positive level 1 evidence) than that for NAC (at best level 2 evidence). Limited data are available for chemoimmunotherapy approaches, but preliminary data support an active research investment. PATIENT SUMMARY: After a comprehensive search of the latest studies examining the role of neoadjuvant and adjuvant chemotherapy for upper tract urothelial cancer, the pooled evidence shows that perioperative chemotherapy was beneficial for prolonging survival; however, the evidence for adjuvant chemotherapy was stronger than that for neoadjuvant chemotherapy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Leow JJ, Chong YL, Chang SL, et al. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. Eur Urol. 2020. PMID: 32798146. doi:10.1016/j.eururo.2020.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。